These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1271 related articles for article (PubMed ID: 34433919)

  • 1. mRNA vaccines for infectious diseases: principles, delivery and clinical translation.
    Chaudhary N; Weissman D; Whitehead KA
    Nat Rev Drug Discov; 2021 Nov; 20(11):817-838. PubMed ID: 34433919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the design and delivery of RNA vaccines for infectious diseases.
    Lokras AG; Bobak TR; Baghel SS; Sebastiani F; Foged C
    Adv Drug Deliv Rev; 2024 Oct; 213():115419. PubMed ID: 39111358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited].
    Jawalagatti V; Kirthika P; Lee JH
    Front Immunol; 2022; 13():884862. PubMed ID: 35592330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2.
    Granados-Riveron JT; Aquino-Jarquin G
    Biomed Pharmacother; 2021 Oct; 142():111953. PubMed ID: 34343897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 mRNA vaccines: Platforms and current developments.
    Szabó GT; Mahiny AJ; Vlatkovic I
    Mol Ther; 2022 May; 30(5):1850-1868. PubMed ID: 35189345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases.
    Rouf NZ; Biswas S; Tarannum N; Oishee LM; Muna MM
    RNA Biol; 2022; 19(1):386-410. PubMed ID: 35354425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2.
    Lee KM; Lin SJ; Wu CJ; Kuo RL
    Biomed J; 2023 Feb; 46(1):70-80. PubMed ID: 36642222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA vaccines: the most recent clinical applications of synthetic mRNA.
    Kwon S; Kwon M; Im S; Lee K; Lee H
    Arch Pharm Res; 2022 Apr; 45(4):245-262. PubMed ID: 35426547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vaccine development based on RNA technology platforms].
    Guo X; Li J; Wang HM; Qiu J; Li Z; Huang F; Li J; Sun XD
    Zhonghua Yu Fang Yi Xue Za Zhi; 2024 Aug; 58(8):1263-1277. PubMed ID: 39142899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
    Milane L; Amiji M
    Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA vaccines against infectious diseases and future direction.
    Aleem MT; Munir F; Shakoor A; Gao F
    Int Immunopharmacol; 2024 Jun; 135():112320. PubMed ID: 38788451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy.
    Deng Z; Tian Y; Song J; An G; Yang P
    Front Immunol; 2022; 13():887125. PubMed ID: 35720301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses.
    Kutikuppala LVS; Kourampi I; Kanagala RSD; Bhattacharjee P; Boppana SH
    Med Sci (Basel); 2024 May; 12(2):. PubMed ID: 38804384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities and challenges to implementing mRNA-based vaccines and medicines: lessons from COVID-19.
    Iqbal SM; Rosen AM; Edwards D; Bolio A; Larson HJ; Servin M; Rudowitz M; Carfi A; Ceddia F
    Front Public Health; 2024; 12():1429265. PubMed ID: 39175908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 mRNA vaccines.
    Huang Q; Zeng J; Yan J
    J Genet Genomics; 2021 Feb; 48(2):107-114. PubMed ID: 34006471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.
    Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP
    Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases.
    Le T; Sun C; Chang J; Zhang G; Yin X
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases.
    Yang L; Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():896958. PubMed ID: 35928814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.